Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Arminder Singh

Internal Medicine Springfield, MA Medical Doctor

NPI 1427088202 CMS profile 291752

50 Maple St Ste 301, Springfield, MA 01103

Open in the dashboard

General payments

$27,545

1,385 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Arminder Singh of Springfield, MA is reported in the CMS Open Payments database as having received $27,545 across 1,385 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,892 174
2024 General $3,947 198
2023 General $3,845 189
2022 General $3,376 162
2021 General $3,809 201
2020 General $3,696 186
2019 General $4,982 275

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Arminder Singh
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Arminder Singh were reported at $3,892. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Arminder Singh Internal Medicine median Middle half National median
2019 $4,982 $159 $48–$570 $163
2020 $3,696 $119 $33–$402 $114
2021 $3,809 $135 $37–$521 $132
2022 $3,376 $141 $42–$496 $149
2023 $3,845 $149 $45–$519 $160
2024 $3,947 $154 $47–$537 $164
2025 $3,892 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,778 120 payments
  2. GlaxoSmithKline, LLC. $2,706 153 payments
  3. Lilly USA, LLC $2,164 115 payments
  4. Amgen Inc. $2,136 116 payments
  5. Pfizer Inc. $1,920 107 payments
  6. Sanofi-Aventis U.S. LLC $1,569 52 payments
  7. AbbVie, Inc. $1,460 80 payments
  8. Janssen Pharmaceuticals, Inc $1,329 56 payments
  9. Novo Nordisk Inc $1,177 57 payments
  10. Merck Sharp & Dohme Corporation $1,002 48 payments
  11. Other $9,305 481 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $27,437 1,376 payments
  2. Education $108 9 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $2,125 114 payments
  2. Repatha $1,537 75 payments
  3. XARELTO $1,133 52 payments
  4. MOUNJARO $1,005 52 payments
  5. FARXIGA $929 38 payments
  6. ELIQUIS $894 45 payments
  7. QULIPTA $739 32 payments
  8. UBRELVY $704 40 payments
  9. Ozempic $676 33 payments
  10. COLOGUARD DNA CAPTURE REAGENTS $560 25 payments
  11. Other $24,564 1,290 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 180 drugs

Part D claims

13,044

Median for Internal Medicine: 777

Drug cost

$3,553,788

Median for Internal Medicine: $73,373

Branded share of claims

35.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 463 $482,460
Eliquis Apixaban Brand 307 $310,370
Farxiga Dapagliflozin Propanediol Brand 332 $305,597
Repatha Sureclick Evolocumab Brand 271 $226,682
Ofev Nintedanib Esylate Brand 12 $155,237
Entresto Sacubitril/Valsartan Brand 126 $143,850
Trulicity Dulaglutide Brand 91 $139,835
Mounjaro Tirzepatide Brand 102 $134,657
Nuplazid Pimavanserin Tartrate Brand 14 $111,377
Wegovy Semaglutide Brand 72 $105,102

The 10 drugs with the highest cost, of 180 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$160,270

Of which drugs: $223

Medicare patients

431

Average age 75

Services billed

5,496

246 women, 185 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Arthritis 43%
Diabetes 32%
Ischemic heart disease 29%
Heart failure 25%
Depression 23%
Osteoporosis 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 12 13 $0

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 44 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
$335 102 —
JARDIANCE
$214 60 —
VOQUEZNA
$195 — —
TRELEGY ELLIPTA
$150 110 —
Repatha
$147 311 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 44 with Patron

Records

1,385 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record